You are here

  • Home
  • Archive
  • Volume 9, Issue 10
  • Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

Article metrics

Article menu
Immunotherapy biomarkers
Original research
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab

 

Online download statistics by month:

Online download statistics by month: October 2021 to January 2026

AbstractFullPdf
Oct 2021718720192
Nov 202123023364
Dec 202116616655
Jan 2022858835
Feb 2022747734
Mar 2022979843
Apr 2022686826
May 2022656532
Jun 2022858737
Jul 20229910037
Aug 202210410554
Sep 2022969648
Oct 2022626325
Nov 2022797938
Dec 2022606028
Jan 2023575936
Feb 2023828323
Mar 2023585920
Apr 2023252519
May 202331318
Jun 2023363616
Jul 2023374032
Aug 202324246
Sep 2023272714
Oct 2023373724
Nov 2023313111
Dec 2023575718
Jan 2024272818
Feb 2024434317
Mar 2024363630
Apr 2024404031
May 202414013827
Jun 2024373624
Jul 2024818327
Aug 2024484616
Sep 2024363782
Oct 20243030138
Nov 2024545529
Dec 2024909221
Jan 2025565620
Feb 202511911931
Mar 2025676825
Apr 2025424224
May 2025434432
Jun 2025313117
Jul 2025220
Jan 2026110
Total361336411584